Jay K. Harness, MD, FACS

Sarcopenia represents a critical yet underrecognized condition affecting older adults and cancer patients. Defined by the European Working Group on Sarcopenia in Older People (EWGSOP2) as “a progressive and generalized skeletal muscle disorder involving accelerated loss of muscle mass and function,” sarcopenia combines low muscle strength, reduced muscle mass or quality, and in severe cases, impaired physical performance.(1)(2) This modern definition recognizes sarcopenia as skeletal muscle failure, analogous to other organ system failures, and can manifest acutely during hospitalization or follow a chronic course with aging and disease.(2) 

Sarcopenia in Aging and Cancer

The intersection of aging, cancer, and sarcopenia creates particularly challenging clinical scenarios. While muscle mass and strength naturally decline with age, cancer and its treatments dramatically accelerate this process through systemic inflammation, metabolic alterations, and direct toxic effects.(3)(4) In cancer patients, sarcopenia can be categorized as pre-existing before cancer onset, cancer-related, or treatment-related.(5) The prevalence reaches 42% overall in cancer populations, with chemotherapy, radiotherapy, and surgery all contributing to muscle loss.(3)(4) 

Cancer treatments exacerbate sarcopenia through multiple mechanisms including increased metabolic stress, reduced physical activity, anorexia, and treatment complications.(6) Studies demonstrate that while functional impairment may precede diagnosis, muscle mass loss accelerates during treatment, particularly in metastatic disease.(7) Importantly, sarcopenia can occur even in patients with normal body mass index or obesity—a condition termed sarcopenic obesity.(4)(8) 

Critical Importance of Detection in Cancer Patients

Detecting and treating sarcopenia in cancer patients has profound clinical implications. Sarcopenic patients experience 44% increased risk of adverse effects during treatment, with particularly high rates in those receiving chemoradiotherapy.(3) Multiple studies show that sarcopenia is associated with higher chemotherapy toxicity, more postoperative complications, reduced treatment compliance, impaired quality of life, and shortened survival.(4)(5)(9) Older adults with sarcopenia experience more than twice the rate of serious non-hematologic toxicity, and those with severe sarcopenia demonstrate significantly worse one-year survival.(7) 

The prognostic value of sarcopenia extends across the cancer continuum, making it a modifiable risk factor that, when addressed, can potentially improve treatment outcomes and survival.(5)(9) This makes routine screening and early intervention essential components of comprehensive, multidisciplinary cancer care.

Measuring Body Composition

Accurate body composition assessment is fundamental to diagnosing sarcopenia. Dual-energy X-ray absorptiometry (DXA) is considered the most effective method for clinical practice, providing accurate estimates of appendicular lean mass with established cutoff values, reproducibility, and relatively low cost.(2) Computed tomography (CT) has emerged as particularly valuable in oncology because it is routinely performed for cancer staging, allowing opportunistic assessment of skeletal muscle area and quality at the third lumbar vertebra without additional radiation or cost.(4)(8) 

Bioimpedance offers a practical in the clinic or hospital alternative that is non-invasive, quick, and useful for screening and serial monitoring.(2)(10) Unlike single-frequency bioelectrical impedance analysis (BIA), bioimpedance spectroscopy (BIS) measures impedance across 256 frequencies, enabling more accurate differentiation between intracellular and extracellular fluid compartments and determination of lean mass. While DXA is considered the standard, systematic reviews confirm bioimpedance can be comparable to CT for sarcopenia detection when appropriately validated.(10) BIS specifically has been validated against CT-based skeletal muscle assessments in oncology populations with early breast cancer, supporting its reliability for radiation free sarcopenia detection in clinical practice.(16) Emerging modalities include nutritional ultrasound, which provides a portable, radiation-free option, though it requires operator expertise and lacks fully validated cutoff points.(11) 

Functional assessments complement imaging-based measurements. Handgrip strength measurement is simple, validated, and highly predictive of adverse outcomes, making it an ideal first-line screening tool.(2) The SARC-F questionnaire can identify at-risk patients, though its sensitivity may be limited in cancer populations.(12)(13) Physical performance tests including gait speed and chair stand tests provide additional functional information correlating with clinical outcomes.(1) 

Evidence-Based Treatment Strategies

Management of sarcopenia requires a multidisciplinary, multimodal approach combining physical exercise and nutritional optimization. Resistance training represents the cornerstone with the strongest evidence base, improving muscle strength, mass, and function through increased protein synthesis and enhanced neuromuscular activation.(2) High-certainty evidence demonstrates that resistance training combined with balance training and nutritional supplementation is most effective for improving quality of life, grip strength, gait speed, and skeletal muscle index.(14) 

Exercise prescriptions typically involve resistance training 2-3 sessions per week for 30-60 minutes, with progressive overload essential for continued improvement.(2) For cancer patients, supervised exercise programs have demonstrated safety and efficacy even during active treatment.(6) 

Nutritional interventions play a complementary but essential role. Current recommendations suggest protein intake of 1.0-1.5 g/kg/day for older adults with sarcopenia, higher than standard recommendations, reflecting anabolic resistance that occurs with aging and illness.(2) Moderate-certainty evidence supports that protein supplementation combined with vitamin D improves handgrip strength and quality of life.(15) For cancer patients, multi-nutrient supplementation addressing multiple deficiencies may be more effective than single-nutrient approaches.(6) 

The most effective approach combines exercise and nutrition in multidisciplinary, coordinated multimodal programs. Network meta-analyses consistently demonstrate that combination interventions produce superior outcomes compared to either modality alone. (14) For cancer patients, this multidisciplinary, multimodal approach should be individualized based on cancer type, treatment stage, functional status, and comorbidities, with early intervention crucial as sarcopenia becomes progressively more difficult to reverse.(5) 

Conclusion

Sarcopenia represents a critical modifiable risk factor profoundly impacting outcomes for cancer patients. Defined by low muscle strength, reduced muscle mass, and impaired physical performance, it affects a substantial proportion of cancer patients through mechanisms related to both aging and cancer treatment. Accurate assessment using validated methods such as DXA, CT, or BIS is essential for diagnosis and monitoring. Evidence-based treatment combining resistance exercise with optimized protein nutrition offers the most effective approach. For all cancer patients, routine screening, early intervention with multimodal programs, and integration of sarcopenia management into comprehensive, multidisciplinary cancer care represent essential steps toward improving treatment tolerance, quality of life, and survival.

References:

1. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Age and Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169.
2. Sarcopenia. Cruz-Jentoft AJ, Sayer AA. Lancet (London, England). 2019;393(10191):2636-2646. doi:10.1016/S0140-6736(19)31138-9.
3. Sarcopenia Is a Prognostic Factor of Adverse Effects and Mortality in Patients with Tumour: A Systematic Review and Meta-Analysis. Zhang Y, Zhang J, Zhan Y, et al. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(6):2295-2310. doi:10.1002/jcsm.13629.
4. Forcing the Vicious Circle: Sarcopenia Increases Toxicity, Decreases Response to Chemotherapy and Worsens with Chemotherapy. Bozzetti F. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2017;28(9):2107-2118. doi:10.1093/annonc/mdx271.
5. Sarcopenia and Malignancies: Epidemiology, Clinical Classification and Implications. Zhang FM, Wu HF, Shi HP, Yu Z, Zhuang CL. Ageing Research Reviews. 2023;91:102057. doi:10.1016/j.arr.2023.102057.
6. What Nutritional Interventions Can Effectively Treat Sarcopenia in Older Adults with Cancer? A Systematic Review. Pattwell M, Gibbs M, Eochagáin CM, et al. Journal of Geriatric Oncology. 2026;17(2):102850. doi:10.1016/j.jgo.2026.102850.
7. Association of sarcopenia and treatment tolerability in older adults with advanced cancer: Secondary analysis of a nationwide NCI Community Oncology Research Program (NCORP) randomized clinical trial. Dunne R, Culakova E, Roeland E, et al. Journal of Clinical Oncology. 2023;41(Suppl 16):12038. doi:10.1200/JCO.2023.41.16_suppl.12038.
8. CT-based Screening of Sarcopenia and Its Role in Cachexia Syndrome in Pancreatic Cancer. Khristenko E, Sinitsyn V, Rieden T, et al. PloS One. 2024;19(1):e0291185. doi:10.1371/journal.pone.0291185.
9. Sarcopenia in Gastrointestinal Cancers. Emori T, Itonaga M, Ashida R, Kitano M. International Journal of Clinical Oncology. 2025:10.1007/s10147-025-02915-x. doi:10.1007/s10147-025-02915-x.
10. Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review. Aleixo GFP, Shachar SS, Nyrop KA, et al. The Oncologist. 2020;25(2):170-182. doi:10.1634/theoncologist.2019-0600.
11. Is Nutritional Ultrasound as Useful and Accurate as Computed Tomography to Assess Sarcopenia in Cancer Patients? A Systematic Review. Luengo-Pérez LM, García-Lobato C, Lázaro-Martín L, Gallardo-Sánchez JD, Guijarro-Chacón MM. Cancers. 2025;17(22):3683. doi:10.3390/cancers17223683.
12. SARC-F for Screening of Sarcopenia Among Older Adults with Cancer. Williams GR, Al-Obaidi M, Dai C, Bhatia S, Giri S. Cancer. 2021;127(9):1469-1475. doi:10.1002/cncr.33395.
13. Unveiling Sarcopenia Prevalence in Post-Cancer Patients: Integrating Functional and Morphological Assessments for Accurate Diagnosis. Meunier M, Massy E, Auréal M, et al. Joint Bone Spine. 2025:106022. doi:10.1016/j.jbspin.2025.106022.
14. Comparative Effectiveness of Exercise and Protein-Based Interventions on Muscle Strength, Mass, and Function in Sarcopenia: A Systematic Review and Network Meta-Analysis. Yan R, Jia S, Lu D, et al. The Journal of Nutrition, Health & Aging. 2025;29(12):100718. doi:10.1016/j.jnha.2025.100718.
15. Nutritional and Pharmacological Interventions for Sarcopenia in Older Adults: A Systematic Review and Network Meta-Analysis. Zhang M, Shen Y, Gao Y, et al. Journal of the American Medical Directors Association. 2025:106038. doi:10.1016/j.jamda.2025.106038.
16.  Sarcopenia detected with bioelectrical impedance versus CT scan and chemotherapy tolerance in patients with early breast cancer. Aleixo, G. F. P.,Valente, S. A., Wei, W., Chen, P.-H., & Moore, H. C. F. Breast Cancer.2023;30(1):101–109. doi:10.1007/s12282-022-01401-w